Last reviewed · How we verify

NCT03807453

Comparison of Scalp Microbiota of the Psoriasis and Seborrheic Dermatitis Patients

Completed Last updated 10 September 2020
What this trial tests

trial testing Microbiota in Psoriasis Vulgaris in 30 participants. Completed in 18 June 2019.

Timeline
25 April 2019
Primary endpoint
18 June 2019
18 June 2019

Quick facts

Lead sponsorIstanbul Medeniyet University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment30
Start date25 April 2019
Primary completion18 June 2019
Estimated completion18 June 2019
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Istanbul Medeniyet University

Who can join

Adults 18 to 80, any sex, with Psoriasis Vulgaris or Seborrheic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A sterile swap specimen taken from the scalp of the patients with psoriasis vulgaris or seborrheic dermatitis and the volunteer control group will be examined in our study. The examples of the microbiota of the patients will be taken both the lesional scalp and the lesion-free part of the scalp. Then, the microbiota differences between the lesioned scalp and the lesion-free scalp of both groups, and the microbiome differences between the two groups and the control group will be evaluated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Microbiota

Trials testing the same drug.

Other recruiting trials for Psoriasis Vulgaris

Currently open trials in the same condition.

Other Istanbul Medeniyet University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03807453.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing